ArticleJPRAS open2026
Hyperdiluted triamcinolone injection therapy for infraorbital herniated fat pads.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infraorbital herniated fat pads are a frequent aesthetic concern and are commonly corrected surgically. Some patients prefer minimally invasive options, yet robust non-surgical volume-reduction approaches remain limited. Intralesional triamcinolone acetonide (TAC) is widely used in dermatology and other fields, and localized cutaneous/subcutaneous atrophy and lipoatrophy are recognized adverse effects. Objective: To report outcomes after treating infraorbital herniated fat pads with hyperdiluted TAC prepared at a 1:20 dilution with normal saline and to discuss steroid-related mechanisms affecting adipose tissue. Materials and methods: We conducted a retrospective case series of nine non-aesthetic-treated patients with infraorbital fat pad protrusion requesting non-surgical management. TAC was hyperdiluted 1:20 with 0.9% normal saline and injected as micro-aliquots into the target fat pad at the lid-cheek junction. Patients received 1-3 sessions at 4-week intervals. Standardized photographs were obtained at baseline and follow-up. Two independent physicians graded improvement using the Global Aesthetic Improvement Scale (GAIS), and patients rated satisfaction using a 5-point Likert scale. Adverse events were recorded. Results: Visible reduction of infraorbital bulging was observed in all patients (9/9). Improvement typically became apparent over several weeks and progressed through follow-up. Mild-to-moderate protrusion generally responded after one or two sessions, whereas more advanced bulging required up to three sessions with partial residual fullness. No serious complications were observed; transient edema, erythema, and tenderness resolved spontaneously. Conclusion: Hyperdiluted TAC (1:20 with normal saline) may provide a conservative, minimally invasive approach to reduce small-volume infraorbital fat protrusion, plausibly through controlled steroid-associated adipose atrophy. Given the known risk of unwanted atrophy, dyspigmentation, and contour irregularity with corticosteroid injections, this approach should be considered investigational and applied cautiously with appropriate anatomical expertise and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.